Vol. 17, Issue 2, 2010January 01, 2010 EDT
Impeding Access to Quality Patient Care and Patient Rights: How Myriad Genetics’ Gene Patents are Unknowingly Killing Cancer Patients and How to Calm the Ripple Effect
Impeding Access to Quality Patient Care and Patient Rights: How Myriad Genetics’ Gene Patents are Unknowingly Killing Cancer Patients and How to Calm the Ripple Effect
Marisa Noelle Pins,
United States Patent and Trademark OfficeMyriad Genetics LaboratoriesInc.University of Utah Research Foundationgene patentsACLUpatient careDNAutility requirementutility examination guidelinesDiamond v. ChakrabartyAmerican Wood-Paper Co. v. Fiber Disintegrating Co.European Patent ConventionNational Institutes of HealthBest Practices for the Licensing of Genomic InventionsSecretary's Advisory Committee on GeneticsHealthand Human ServicesOrganisation for Economic Co-Operation and Development
Marisa Noelle Pins, Impeding Access to Quality Patient Care and Patient Rights: How Myriad Genetics’ Gene Patents Are Unknowingly Killing Cancer Patients and How to Calm the Ripple Effect, 17 Journal of Intellectual Property 377 (2010).